{{Rsnum
|rsid=4937
|Gene=POLR2C
|Chromosome=16
|position=57465990
|Orientation=plus
|GMAF=0.2741
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=POLR2C
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 52.2 | 39.8 | 8.0
| HCB | 37.2 | 45.3 | 17.5
| JPT | 24.8 | 51.3 | 23.9
| YRI | 95.9 | 4.1 | 0.0
| ASW | 91.2 | 8.8 | 0.0
| CHB | 37.2 | 45.3 | 17.5
| CHD | 34.9 | 49.5 | 15.6
| GIH | 58.4 | 36.6 | 5.0
| LWK | 86.4 | 13.6 | 0.0
| MEX | 41.4 | 41.4 | 17.2
| MKK | 90.4 | 9.6 | 0.0
| TSI | 57.8 | 40.2 | 2.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20091185
|Title=MGMT -535G&gt;T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}